Compare Deere & Company (DE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Sana Biotechnology Inc — how do they compare? Deere & Company trades at $615.56 (market cap $166.81B), while Sana Biotechnology Inc trades at $3.75 (market cap $1.13B). The key difference: Deere & Company is far larger — about 147.6× Sana Biotechnology Inc's market cap, and Deere & Company pays a 1.05% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DE | SANA | |
|---|---|---|
Market Cap | $166.81B | $1.13B |
Sector | Industrials | Health |
52-Week High | $662.49 | $5.92 |
52-Week Low | $439.11 | $2.68 |
Enterprise Value | $221.63B | $1.05B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $609.28, down 1.86% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving averages, but oscillators are neutral. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $6.55 surpassing the $5.70 estimate. Revenue declined to $44.67B in 2025, with net income margin at 10.33%. Analyst consensus is a Moderate Buy, with a price target of $669.79, implying potential upside. The company maintains a solid balance sheet with $8.48B in cash, though debt levels remain elevated.
The outlook for DE is cautiously optimistic, driven by earnings beats and analyst confidence, but tempered by revenue declines and agricultural cycle risks. Investment opportunity lies in the valuation gap to the consensus target, while key risks include weak North American demand and margin pressure highlighted in recent industry reports. The stock's performance hinges on upcoming Q3 2026 earnings on August 20, 2026.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
